The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Q&A: Odds of surviving cancer drop drastically when credit score dips

2.

CAR-T cell therapy for cancer causes 'brain fog,' study shows

3.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

4.

Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer

5.

Geriatric Assessment, QoL Correlate With OS in Older Patients with Pancreatic Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot